11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA. (Q46197457)

20 December 2017

title

11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA. (English)

1 reference

20 December 2017

0 references

0 references

Martin Braddock

1

1 reference

20 December 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

20 December 2017

Expert Opinion on Investigational Drugs

published in

1 reference

20 December 2017

volume

16

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

page(s)

909-917

1 reference

20 December 2017

Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Targeting Syk as a treatment for allergic and autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Rapid desensitization for hypersensitivity reactions to chemotherapy agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

The ERK/MAPK pathway, as a target for the treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Therapeutic options for 5-lipoxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

The many roles of chemokines and chemokine receptors in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

B cell abnormalities in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

T cell epitope-specific immune therapy for rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Overcoming antigenic diversity and improving vaccines using DNA shuffling and screening technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

DNA shuffling and screening strategies for improving vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Treatment of interferon-alpha for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Validation of the Anti-Inflammatory Properties of Small-Molecule I B Kinase (IKK)-2 Inhibitors by Comparison with Adenoviral-Mediated Delivery of Dominant-Negative IKK1 and IKK2 in Human Airways Smooth Muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.6.909

10.1517/13543784.16.6.909

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

17501702

1 reference

20 December 2017